title: Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease.
abstract: Rituximab was trialed in a refractory Vogt-Koyanagi-Harada disease (VKH). A 10-year-old girl with panuveitis recalcitrant to treatment, including corticosteroids, was diagnosed with VKH 20 months later. Following rituximab at 0, 1, 6, and 18 months, response was favorable after the second dose, usual life activity resumed after the third dose (uveitis was inactivated and vision improved), and eyes stabilized 9 months after the fourth dose. Rituximab is effective in the treatment and long-term control of advanced, pediatric VKH.
authors.affiliation: a Department of Pediatrics , University of Kufa, College of Medicine, Al- Zahraa Teaching Hospital , Najaf , Iraq.
authors.forename: Raid M R
authors.initials: RMR
authors.lastname: Umran
authors.affiliation: b Department of Physiology , University of Kufa, College of Medicine, Al Sader Teaching Hospital , Najaf , Iraq.
authors.forename: Zaid Y H
authors.initials: ZYH
authors.lastname: Shukur
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D019233:Retreatment; D000069283:Rituximab / Q000627:therapeutic use*; D016896:Treatment Outcome; D014607:Uveomeningoencephalitic Syndrome / Q000188:drug therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D005938:Glucocorticoids; D000069283:Rituximab
keywords: Pediatric; Rituximab; Uveitis; Vogt–Koyanagi–Harada